Skip to Main Content
 
Capabilities

Sigmapharm Laboratories Wins Claim Construction

 
November 01, 2018

Related Industry:

Life Sciences
 
Case Study

Husch Blackwell client Sigmapharm Laboratories, LLC scored a victory in bringing to market a therapeutic equivalent of Eliquis. Sigmapharm argued for a claim construction of “pharmaceutically acceptable salt,” and the Court adopted Sigmapharm’s proposed construction verbatim.

This result is one of the first major steps in obtaining a favorable outcome for our client and potentially saving billions of dollars for payors. Among 25 original defendants—9 of which remain in the litigation—Husch attorneys took the lead in briefing the position, and Phil Segrest handled the oral argument.

Professionals:

Don J. Mizerk

Partner

Dustin L. Taylor

Associate

David Gerasimow

Associate

Syed Rizvi, Ph.D.

Senior Scientific Advisor

Robert J. Holbrook, Ph.D.

Scientific Advisor